ArticleACS nanoscience Au2026
Recombinant Protein Nanoparticles for Dual-Stage Inhibition of SARS-CoV‑2 Infection.
Article in ACS nanoscience Au, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recombinant proteins exhibit significant promise as antiviral therapeutics. Here, we present a nanotherapeutic platform that, owing to its unique ability to self-assemble, can present multiple functionalities at the liquid-liquid interface. We genetically modified the sequence of an amphiphilic plant-derived protein called oleosin to induce spontaneous self-assembly into micellar nanoparticles. Using SARS-CoV-2 as a model, we demonstrate the potential of a recombinant protein nanoparticle to inhibit two different stages of viral infection. Oleosin variants were engineered to present miniproteins 1) that block the SARS-CoV-2 spike protein binding with human ACE2 receptors and 2) that inhibit virus-cell membrane fusion. Micellar nanoparticles assembled from these proteins are multivalent and bifunctional and achieved potent inhibition of the virus with an IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.